Consensus earnings for the current quarter by the 26 sell-side analysts covering the stock is an estimate of $2.24 per share, which would be $0.84 better than the year-ago quarter and a $0.02 sequential increase. Investors should also note that the full-year EPS estimate of $8.87 is a $2.34 improvement when compared to the previous year’s annual results.

The quarterly earnings estimate is predicated on a consensus revenue forecast of $1.91 Billion. If reported, that would be a 34.51% increase over the year-ago quarter.

The average price target for BIIB shares is $289.96, which is 1.03% below where the stock opened this morning.

Biogen Idec Inc. (NASDAQ:BIIB), discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders in the Worldwide. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003.

Sharing the News

Follow us for the Latest news

Jutia Group Newsletter

Keywords: Business, Markets, NASDAQ:BIIB, Stock

NYSE, NASDAQ, Market Data, Earnings Estimates, Analyst Ratings and Key Statistics provided via Yahoo Finance, unless otherwise specified. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Jutia Group will not be liable for any errors, incompleteness or delays, or for any actions taken in reliance on the data displayed herein.